Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Clearmind Medicine Inc. Common Shares (CMND)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CMND (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.13% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.78M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -1.31 | 52 Weeks Range 0.80 - 2.30 | Updated Date 06/29/2025 |
52 Weeks Range 0.80 - 2.30 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.23% | Return on Equity (TTM) -139.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 168145 | Price to Sales(TTM) - |
Enterprise Value 168145 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.79 | Shares Outstanding 5379440 | Shares Floating 4864790 |
Shares Outstanding 5379440 | Shares Floating 4864790 | ||
Percent Insiders 2.8 | Percent Institutions 11.19 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Clearmind Medicine Inc. Common Shares
Company Overview
History and Background
Clearmind Medicine Inc. is a biotechnology company focused on researching, developing, and commercializing novel psychedelic-derived therapeutics to solve widespread and underserved health problems. Founded in 2020, it is headquartered in Vancouver, Canada. They are pursuing therapeutic programs for various addictions.
Core Business Areas
- Drug Discovery and Development: Developing novel psychedelic-derived therapeutics for mental health disorders and addiction.
- Clinical Trials: Conducting preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
- Intellectual Property: Protecting its drug candidates and technologies through patents and other forms of intellectual property.
Leadership and Structure
Dr. Adi Zuloff-Shani is the CEO of Clearmind. The company operates with a scientific advisory board and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- MEAI-Based Therapies: Clearmind is focused on developing therapies based on MEAI (5-Methoxy-2-Aminoindane). It is in preclinical and clinical stages for the treatment of alcohol use disorder (AUD) and binge eating disorder (BED). Competitors include companies developing similar therapies and traditional addiction treatments.
Market Dynamics
Industry Overview
The psychedelic therapeutics industry is growing rapidly, driven by increasing awareness of mental health issues and the potential of psychedelic compounds to treat these conditions. Significant investments are being made in research and development, with several companies pursuing clinical trials for various psychedelic therapies.
Positioning
Clearmind is positioning itself as an innovator in the psychedelic therapeutics space, focusing on developing novel MEAI-based therapies. Its competitive advantage lies in its proprietary technology and its focus on specific underserved health problems like binge eating disorder.
Total Addressable Market (TAM)
The TAM for addiction and mental health treatments is substantial, estimated in the billions of dollars annually. Clearmind's position with MEAI products can address a portion of that TAM.
Upturn SWOT Analysis
Strengths
- Novel MEAI-based therapies
- Strong intellectual property portfolio
- Focus on underserved markets
- Experienced management team
Weaknesses
- Early stage of development
- Limited financial resources
- Dependence on clinical trial outcomes
- High regulatory hurdles
Opportunities
- Growing demand for mental health treatments
- Increasing acceptance of psychedelic therapies
- Potential for strategic partnerships
- Expansion into new indications
Threats
- Regulatory uncertainty
- Competition from established pharmaceutical companies
- Clinical trial failures
- Funding challenges
Competitors and Market Share
Key Competitors
- ATAI
- COMP
- GHRS
- MNMD
Competitive Landscape
Clearmind is a smaller player in the psychedelic therapeutics space compared to larger, better-funded companies. Its competitive advantage lies in its novel MEAI compounds and its focus on niche indications.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily in terms of R&D progress and intellectual property expansion.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of MEAI-based therapies. Analyst estimates are not widely available due to the company's early stage.
Recent Initiatives: Recent initiatives include advancing clinical trials for AUD and BED, and expanding its intellectual property portfolio.
Summary
Clearmind Medicine Inc. is an early-stage biotechnology company in the promising psychedelic therapeutics market. Its focus on novel MEAI-based therapies for underserved conditions like binge eating disorder could provide an advantage. However, it faces significant risks typical of biotech companies, including regulatory hurdles and clinical trial uncertainties. Its success hinges on advancing its pipeline and securing sufficient funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Clearmind Medicine Inc. Investor Relations
- Company Filings
- Market Research Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. The analysis is based on available information and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clearmind Medicine Inc. Common Shares
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2021-08-16 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | |
Full time employees - | |||
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. The company develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post traumatic stress disorder and other health conditions. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is based in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.